Drug Transporter (DT) Information

General Information of DT
DT ID DTD0007
Gene Name SLC47A1
Protein Name Multidrug and toxin extrusion protein 1
Gene ID
55244
UniProt ID
Q96FL8
TCDB ID
2.A.66.1.14
3D Structure

Modelled DT Structure

Method: homology modeling

Template PDB: 5XJJ_A

Identity: 31.891%

Minimized Score: -1261.317 kcal/mol

Detail: Structure Info

Synonyms MATE-1; MATE1; SLC47A1; Solute carrier family 47 member 1; hMATE-1
DT Family Multidrug/Oligosaccharidyl-Lipid/Polysaccharide (MOP) Flippase Superfamily
Multi Antimicrobial Extrusion (MATE) Family
Tissue Specificity Highly expressed in the liver , the kidney, and skeletal muscle, lower expression in the adrenal gland, testes, and heart
Function This transporter is responsible for secretion of cationic drugs across the brush border membranes. This transporter is for tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, N-methylnicotinamide (NMN), metformin, creatinine, guanidine, procainamide, topotecan, estrone sulfate, acyclovir, ganciclovir and also the zwitterionic cephalosporin, cephalexin and cephradin. Seems to also play a role in the uptake of oxaliplatin. Able to transport paraquat (PQ or N,N-dimethyl-4-4'-bipiridinium); a widely used herbicid.
Disease(s) Cytomegalovirus infections [ICD-11: 1D82]
Malaria [ICD-11: 1F40]
Ovarian cancer [ICD-11: 2C73]
Type 2 diabetes [ICD-11: 5A11]
Ventricular arrhythmias [ICD-11: BC71]
Herpes simplex virus infection [ICD-11: 1F00]
Maintenance of normal sinus rhythm [ICD-11: BC81.3]
Gram-positive bacteria infections [ICD-11: 1A00-1H0Z]
Endogenous Substrate(s) N,N-dimethyl-4-4'-bipiridinium; N-methylnicotinamide; Cephalosporins; Creatinine; Guanidine
Variability Data of This Drug Transporter (DT)

Regulatory Variability Data of This DT (VARIDT 3.0)

(α) Microbiota Influence of This DT
Microbiota Influence (MBI)

(β) Post-translational Modification of This DT
Post-translational Modification (PTM)

(γ) Transcriptional Regulation of This DT
Transcriptional Regulation (TSR)

(δ) Epigenetic Regulation of This DT
Epigenetic Regulation (EGR)

(ε) Exogenous Modulation of This DT
Exogenous Modulation (EGM)

Structural Variability Data of This DT (VARIDT 2.0)

(β) Inter-species Structural Differences
Inter-species Structural Differences (ISD)

(δ) Xenobiotics-regulated Structural Variability
Xenobiotics-regulated Structural Variability (XSV)

General Variability Data of This DT (VARIDT 1.0)

(α) Genetic Polymorphisms of This DT
Genetic Polymorphisms of This DT (GPD)

(β) Disease-specific Protein Abundances of This DT
Disease-specific Protein Abundances of This DT (DPAD)

(γ) Species- and Tissue-specific DT Abundances
Species/Tissue-specific Protein Abundances of This DT (S/TPAD)
Molecular Transporting Profile of This DT

Full List of Drug(s) Transported by This DT

 Approved Drug

 Click to Show/Hide the Full List of Drug:          15 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Abemaciclib
 Approved Drug Info Breast cancer 2C60-2C6Z [1]
Acyclovir
 Approved Drug Info Shingles 1.00E+91 [2]
Auranofin
 Approved Drug Info Rheumatoid arthritis FA20 [3]
Cephalexin
 Approved Drug Info Gram-positive bacteria infections 1A00-1H0Z [4]
Chloroquine
 Approved Drug Info Malaria 1F40 [5]
Cimetidine
 Approved Drug Info Acid reflux disorder DA22 [2]
Dofetilide
 Approved Drug Info Maintenance of normal sinus rhythm BC81.3 [6]
Emtricitabine
 Approved Drug Info Hepatitis B virus infection 1E51.0, 1E50.1 [7]
Enoxacin
 Approved Drug Info Gonorrhea 1A70-1A7Z [8]
Estrone sulfate
 Approved Drug Info Menopausal symptoms MF32 [2]
Ganciclovir
 Approved Drug Info Cytomegalovirus infections 1D82 [2]
Metformin
 Approved Drug Info Type 2 diabetes 5A11 [9]
Procainamide
 Approved Drug Info Ventricular arrhythmias BC71 [2]
Pyrimethamine
 Approved Drug Info Isosporiasis 1A33.Z [10]
Topotecan
 Approved Drug Info Ovarian cancer 2C73 [2]

 Clinical Trial Drug

 Click to Show/Hide the Full List of Drug:            1 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Tetraethylammonium
 Phase 2 Drug Info Hyperlipidaemia 5C8Z [11]

 Withdrawn, Discontinued or Preclinical Drug

 Click to Show/Hide the Full List of Drug:            2 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Mephenoxalone
 Preclinical Drug Info Anxiety MB24.3 [12]
N-methylpyridinium
 Preclinical Drug Info Colon cancer 2B90.Z [2]

Endogenous Metabolites (EMs) Handled by This DT

 Endogenous Metabolites (EMs)

 Click to Show/Hide the Full List of EMs:            1 EMs in Total
EM Name PubChem CID Detail Experimental Material Ref
Creatinine
588
EM Info Identified using MATE1-overexpressing HEK293 cells [13]

Drug-DT Affinity Assessed by Cell Line

 Approved Drug

 Click to Show/Hide the Full List of Drug:            9 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
Acyclovir Approved Drug Info Human embryonic kidney cells (HEK293)-MATE1 Km = 2640 microM [2]
Cimetidine Approved Drug Info Human embryonic kidney cells (HEK293)-MATE1 Km = 170 microM [2]
Estrone sulfate Approved Drug Info Human embryonic kidney cells (HEK293)-MATE1 Km = 470 microM [2]
Ganciclovir Approved Drug Info Human embryonic kidney cells (HEK293)-MATE1 Km = 5120 microM [2]
Metformin Approved Drug Info Human cervical cancer cell line (Hela)-MATE1 Km = 202 microM [9]
Metformin Approved Drug Info Human embryonic kidney cells (HEK293)-MATE1 Km = 227 microM [14]
Metformin Approved Drug Info Human embryonic kidney cells (HEK293)-MATE1 Km = 780 microM [2]
Procainamide Approved Drug Info Human embryonic kidney cells (HEK293)-MATE1 Km = 1230 microM [2]
Topotecan Approved Drug Info Human embryonic kidney cells (HEK293)-MATE1 Km = 70 microM [2]

 Clinical Trial Drug

 Click to Show/Hide the Full List of Drug:            2 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
Tetraethylammonium Phase 2 Drug Info Human embryonic kidney cells (HEK293)-MATE1 Km = 220 microM [11]
Tetraethylammonium Phase 2 Drug Info Human embryonic kidney cells (HEK293)-MATE1 Km = 380 microM [15]

 Withdrawn, Discontinued or Preclinical Drug

 Click to Show/Hide the Full List of Drug:            3 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
N-methylpyridinium Preclinical Drug Info Human embryonic kidney cells (HEK293)-MATE1 Km = 16 microM [11]
N-methylpyridinium Preclinical Drug Info Human embryonic kidney cells (HEK293)-MATE1 Km = 100 microM [2]
Paraquat Investigative Drug Info Human embryonic kidney cells (HEK293)-MATE1 Km = 169 microM [14]
References
1 Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate. Clin Pharmacol Ther. 2019 May;105(5):1187-1195.
2 Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
3 Selection and characterization of a human ovarian cancer cell line resistant to auranofin. Oncotarget. 2017 Oct 9;8(56):96062-96078.
4 Reduced renal clearance of a zwitterionic substrate cephalexin in MATE1-deficient mice. J Pharmacol Exp Ther. 2010 Aug;334(2):651-6.
5 Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine. Antimicrob Agents Chemother. 2011 Jul;55(7):3091-8.
6 FDA Drug Development and Drug Interactions
7 Emtricitabine is a substrate of MATE1 but not of OCT1, OCT2, P-gp, BCRP or MRP2 transporters. Xenobiotica. 2017 Jan;47(1):77-85.
8 Functional characterization of multidrug and toxin extrusion protein 1 as a facilitative transporter for fluoroquinolones. J Pharmacol Exp Ther. 2009 Feb;328(2):628-34.
9 Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol. 2010 Apr;298(4):F997-F1005.
10 Expression of Organic Anion Transporter 1 or 3 in Human Kidney Proximal Tubule Cells Reduces Cisplatin Sensitivity. Drug Metab Dispos. 2018 May;46(5):592-599.
11 A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):17923-8.
12 Preclinical and clinical evidence for the collaborative transport and renal secretion of an oxazolidinone antibiotic by organic anion transporter 3 (OAT3/SLC22A8) and multidrug and toxin extrusion protein 1 (MATE1/SLC47A1). J Pharmacol Exp Ther. 2010 Sep 1;334(3):936-44.
13 Effect of tyrosine kinase inhibitors on renal handling of creatinine by MATE1. Sci Rep. 2018 Jun 18;8(1):9237.
14 Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function. Pharmacogenomics J. 2009 Apr;9(2):127-36.
15 The role of microRNA in the delayed negative feedback regulation of gene expression. Biochem Biophys Res Commun. 2007 Jul 6;358(3):722-6.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.